MedTrace Logo

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma

NCT00416832 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 648

Last updated 2020-03-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells.

PURPOSE: This phase II trial is studying the side effects and how well giving combination chemotherapy together with radiation therapy works in treating young patients with Hodgkin's lymphoma.

Conditions

Interventions

DRUG

cyclophosphamide

DRUG

dacarbazine

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

prednisone

DRUG

procarbazine hydrochloride

DRUG

vincristine sulfate

RADIATION

radiation therapy

Sponsors & Collaborators

  • Christine Mauz-Körholz

    lead OTHER

Principal Investigators

  • Dieter Koerholz, MD · Martin-Luther-Universität Halle-Wittenberg

Study Design

Purpose
TREATMENT

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2005-12-31
Completion
2005-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00416832 on ClinicalTrials.gov